Nuevos tratamientos y métodos de abordaje de la colitis ulcerosa

ABCD. https://abcd.org.br/B. Accessed November 18, 2019.
en-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 2011;33:987-995.
Bonovas S, Lytras T, Nikolopoulos G, et al. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47:454-465.
Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol. 1997;151:97-110.
Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7:322-337.
Cholapranee A, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45:1291-1302.
Colombel J-F, Narula N, Peyrin-Biroulet L, et al. Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology. 2017;152:351-361.
Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends Pharm Sci. 2017;38:127-142.
Danese S, Grisham M, Hodge J, et al. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol. 2016;310:G155-G162.
Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for moderately to severely active ulcerative colitis. Ann Intern Med. 2014;160:704-711.
Dhingra R, Kedia S, Mouli VP, et al. Evaluating clinical, dietary, and psychological risk factors for relapse of ulcerative colitis in clinical, endoscopic, and histological remission. J Gastroenterol Hepatol. 2017;32:1698-1705.
Dias CC, Rodrigues PP, da Costa-Pereira A, et al. Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies. J Crohns Colitis. 2015:156-163.
Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699-710.
Feuerstein JD, Moss AC, Farraye FA, et al. Ulcerative colitis. Mayo Clin Proc. 2019;94:1357-1373.
Gispert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterology. 2009;104:760-767.
Jonathas Luis Groetares Ferreira and Rodrigo Arnaldo Scarpel. Patient Segmentation using Clustering and Classification Methods.
Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11:769-784.
Jornada do paciente complete. https://abcd.org.br/wp-content/uploads/2018/01/JORNADA_DO_PACIENTE_COMPLETA.pdf?utm_source=jornada&utm_medium=site&utm_campaign=completo. Accessed November 18, 2019.
Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720-727.
Kotze PG, Underwood FE, Damião AOMC, et al. Progression of inflammatory bowel diseases throughout Latin America and the Caribbean: a systematic review. Clin Gastroenterol Hepatol. 2019 [Epub ahead of print].
Kotze PG, Ma C, Almutairdi A, et al. Clinical utility of ustekinumab in Crohn’s disease. J Inflamm Res. 2018;11:35-47.
Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504-1517.
Machado M, Steinwurz F, Zaltman C, et al. Mapping patient journey in inflammatory bowel disease in Brazil. Journal of Crohn’s and Colitis. 2019 [Epub ahead of print].
Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017:649-670.
Moschen AR, Tilg H, Raine T. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat Rev Gastroenterol Hepatol. 2019;16:185-196.
Pagnini C, Pizarro TT, Cominelli F. Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor. Front Pharmacol. 2019;10:671.
Peyrin-Biroulet L. Defining severity in inflammatory bowel disease. Gastroenterol Hepatol. 2015;11:474-476.
Quaresma AB, Coy CSR, Damião AOMC, et al. Biological therapy penetration for inflammatory bowel disease in Latin America: current status and future challenges. Arq Gastroenterol. 2019;56:318-322.
Reinisch W, Reinink AR, Higgins PDR. Factors associated with poor outcomes in adults with newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:635-642.
Rocchi A, Benchimol EI, Bernstein CN, et al. Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol. 2012;26:811-818.
Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114:384-413.
Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723-1736.
Sands BE, Peyrin-Biroulet L, Loftus EV, et al. Vedolizumab shows superior efficacy versus adalimumab: results of varsity – the first head-to-head study of biologic therapy for moderate-to-severe ulcerative colitis. Gastroenterology. 2019;156(Suppl1):S81. Abstract 416a.
Sands BE, Peyrin-Biroulet L, Loftus EV, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381:1215-1226.
Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201-1214.
Schreiber S, Panés J, Louis E, et al. Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey. BMC Gastroenterol. 2012;12:108.
Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol. 2003;3:900-911.
Singh S, Fumery M, Sandborn WJ, et al. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47:162-175.
Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN study). Scand J Gastroenterol. 2009;44:431-440.
Trigo-Vicente C, Gimeno-Ballester V, García-López S, et al. Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis. Int J Clin Pharm. 2018;40:1411-1419.
Ungaro R, Colombel J-F, Lissoos T, et al. A treat-to-target update in ulcerative colitis: a systematic review. Am J Gastroentelogy. 2019;114:874-883.
Vickers AD, Ainsworth C, Mody R, et al. Systematic review with network meta-analysis: comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis. PLoS One. 2016;11:e0165435.
Yamamoto-Furusho JK, Sarmiento-Aguilar A, Toledo-Mauriño JJ, et al. Incidence and prevalence of inflammatory bowel disease in Mexico from a nationwide cohort study in a period of 15 years (2000-2017). Medicine. 2019;98:e16291.
Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterology. 2011;106:685-698.

No Results